{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T16:24:15.238537",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 93,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "survival",
        "long-term survival",
        "5-year survival",
        "improved survival",
        "patient survival",
        "overall survivability",
        "progression-free survival (PFS)",
        "progression-free survival (RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "disease-free survivorship",
        "annual mortality",
        "perioperative mortality",
        "mortality (all-cause mortality defined as death due to any cause)",
        "treatment-related mortality",
        "deaths"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; modified RECIST for liver disease, mRECIST)",
        "tumor response rate",
        "tumour response (BCLC assessment system)",
        "tumour response (multiphase computed tomography with contrast)",
        "tumour response (magnetic resonance imaging)",
        "tumour reduction",
        "overall response rate (ORR)",
        "response rate",
        "response rates",
        "partial response (PR)",
        "partial response (radiological, independently assessed)",
        "minor response (radiological, independently assessed; reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "stable disease (SD)",
        "stable disease for at least 16 weeks (radiological, independently assessed)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "clinical benefit rate (CBR)",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "local control",
        "local tumor control",
        "bridge to transplant",
        "recurrence",
        "local recurrence",
        "early detection of local recurrence",
        "early detection of de novo tumor",
        "pulmonary metastasis",
        "tumour seeding"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "tumour progression (RECIST 1.1)",
        "disease progression",
        "progression-free survival",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time-to-progression",
        "time to deterioration",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30)",
        "time-to-symptom worsening (TSW; EORTC QLQ-HCC18)",
        "time-to-symptom worsening (TSW; EQ-5D VAS)",
        "time-to-symptom worsening (TSW; EQ-5D HUI)",
        "disease status (ECOG performance status)",
        "prognosis (BCLC staging system)",
        "prognosis",
        "tumor characteristics",
        "overall medical condition",
        "detection of early hepatocellular carcinoma"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (grade 3 and higher or serious/major adverse events)",
        "adverse events (grade ≥ 3)",
        "adverse events (< 25% difference)",
        "adverse events (serious, grade 3/4)",
        "adverse events leading to discontinuation",
        "discontinuation of treatment due to adverse events",
        "drug withdrawal due to adverse events",
        "dropout rate for critical toxicity",
        "toxicity",
        "safety (side effects)",
        "serious adverse events",
        "serious complications",
        "complications",
        "complication rate (post treatment complication)",
        "undesirable effects",
        "infections",
        "lymphopenia",
        "anorexia",
        "hypophosphataemia",
        "haemorrhage",
        "bleeding",
        "tumour haemorrhage",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "haemorrhagic events",
        "hemorrhage",
        "rebleeding prophylaxis outcomes",
        "hypertension",
        "arterial hypertension",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand-foot skin reaction (grade 3/4)",
        "proteinuria",
        "dysphonia",
        "alopecia",
        "erythema",
        "pruritus",
        "rash",
        "dry skin",
        "skin desquamation",
        "weight loss",
        "decreased appetite",
        "fatigue",
        "pain",
        "abdominal pain",
        "joint pain",
        "arthralgia",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "diarrhoea (grade 3/4)",
        "nutrition-related adverse events",
        "secondary cancer",
        "dyspnoea",
        "pleural effusion",
        "respiratory failure",
        "cerebral vascular accident",
        "ischaemic stroke",
        "myocardial infarction",
        "cardiovascular arrest",
        "sudden death",
        "treatment-related deaths",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "hepatotoxicity",
        "liver failure",
        "hepatic insufficiency",
        "impaired liver function",
        "liver-related morbidity",
        "liver function",
        "liver function (Child Pugh scale)",
        "portal vein thrombosis",
        "thromboembolic events",
        "hypothyroidism",
        "neurotoxicity",
        "morbidity",
        "intraoperative complications",
        "postoperative softening",
        "gallbladder abscess",
        "lymphoedema (grade 3/4)",
        "intestinal failure",
        "sepsis",
        "complications of portal hypertension",
        "complications of cirrhosis"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "sudden death"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "discontinuation of treatment due to adverse events",
        "drug withdrawal due to adverse events",
        "dropout rate for critical toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "quality of life",
        "health-related quality of life (HRQoL)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "quality of life (measured with a validated and reliable instrument)",
        "EORTC QLQ-C30",
        "EORTC QLQ-30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-G",
        "FACT-G GP5",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "EQ-5D",
        "EQ-5D-5L",
        "EQ-5D-3L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D visual analogue scale (VAS)",
        "EQ-5D health utility index (HUI)",
        "SF-36",
        "visual analogue scale"
      ],
      "functional_status": [
        "disease status (ECOG performance status)"
      ],
      "symptom_measures": [
        "pain",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30)",
        "time-to-symptom worsening (TSW; EORTC QLQ-HCC18)",
        "time-to-symptom worsening (TSW; EQ-5D VAS)",
        "time-to-symptom worsening (TSW; EQ-5D HUI)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost effectiveness",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "measured patient outcomes",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "early detection of local recurrence",
        "early detection of de novo tumor",
        "detection of early hepatocellular carcinoma",
        "tumor characteristics",
        "overall medical condition",
        "bridge to transplant"
      ],
      "biomarkers": [
        "blood and tumour biomarkers",
        "elevated alpha-fetoprotein (AFP) in follow-up"
      ],
      "pharmacokinetics": [
        "pharmacokinetics",
        "plasma pharmacokinetics",
        "PK/PD relationship",
        "pharmacokinetic parameters"
      ],
      "laboratory_and_monitoring": [
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography"
      ]
    }
  }
}